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A B S T R A C T
Purpose
Compared with white women, black women experience a disproportionate burden of aggressive
breast cancer for reasons that remain unknown and understudied. In the first study of its kind, we
determined the distribution of molecular subtypes of invasive breast tumors in indigenous black
women in West Africa.
Patients and Methods
The study comprised 507 patients diagnosed with breast cancer between 1996 and 2007 at six
geographic regions in Nigeria and Senegal. Formalin-fixed and paraffin-embedded sections were
constructed into tissue microarrays and immunostained with 15 antibodies. Five molecular
subtypes were determined, and hierarchical cluster analysis was conducted to explore subgroups
for unclassified cases.
Results
The mean ( standard deviation) age of 378 patients in the first cohort was 44.8  11.8 years, with
the majority of women presenting with large (4.4  2.0 cm) high-grade tumors (83%) in advanced
stages (72% node positive). The proportions of estrogen receptor (ER) –positive, progesterone
receptor–positive, and human epidermal growth factor receptor 2 (HER2) –positive tumors were
24%, 20%, and 17%, respectively. Triple negativity for these markers was predominant, including
basal-like (27%) and unclassified subtype (28%). Other subtypes were luminal A (27%), luminal B
(2%), and HER2 positive/ER negative (15%). The findings were replicated in the second cohort of
129 patients. The unclassified cases could be grouped into a bad prognosis branch, with
expression of vascular endothelial growth factor, B-cell lymphoma extra-large protein, and Cyclin
E, and a good prognosis branch, with expression of B-cell lymphoma protein 2 and Cyclin D1.
Conclusion
These findings underscore the urgent need for research into the etiology and treatment of the
aggressive molecular subtypes that disproportionately affect young women in the African diaspora.
J Clin Oncol 27:4515-4521. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Among women born and raised in the United States,
black women have a lower incidence rate of breast
cancer but poorer survival than white women.1 So-
cioeconomic factors that lead to later stage at diag-
nosis and limited access to quality health care
contribute substantially to this disparity.2,3 How-
ever, differences in outcomes were still observed be-
tween black and white patients after accounting for
stage, socioeconomic status, and age.4,5 Breast can-
cer in African Americans is more likely to be early-
onset, higher grade, and estrogen receptor (ER)
negative compared with breast cancer in white
Americans.2,3,6 A British study also found that black
patients presented at a younger age with a higher
frequency of grade 3, ER-negative tumors and had
poorer outcomes than white patients with breast
cancer.7 Additional tumor features that differ be-
tween black and white patients may explain these
differences in outcomes, but there is paucity of data.
Women of African ancestry remain understudied,
despite the significant scientific advances of the
past decade.
Gene expression profiling studies have
identified at least four breast cancer subtypes and
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demonstrated the ability to predict clinical outcomes independent
of other prognostic factors.8,9 Luminal A and B subtypes are hor-
mone receptor positive and have favorable clinical outcomes. Human
epidermal growth factor receptor 2 (HER2) –positive/ER-negative
subtype is characterized by overexpression of HER2, and basal-like
subtype is negative for ER, progesterone receptor (PR), and HER2;
both subtypes had poor outcomes before the advent of trastuzumab as
molecularly targeted therapy for HER2-positive breast cancer. Immu-
nohistochemical (IHC) markers have been used to define these sub-
types with similar prognostic value,10,11 which allows for breast cancer
subtype assignment in large-scale epidemiologic studies and clinical
practice. Basal-like, or more generally triple-negative (ER negative/PR
negative/HER2 negative) breast cancer, is reportedly more prevalent
in African Americans than in their white counterparts.11-14
Although the age-standardized incidence rate of breast cancer in
Africa is only a quarter of the rate in North America, the mortality rate
in Africa is close to that in North America.15 In West Africa, the
founder population of most African Americans, breast cancer is a
virulent disease of young women.16,17 Unfortunately, there has been
minimal research output to guide cancer control policies in impover-
ished African countries. To our knowledge, this is the first interna-
tional study to examine the proportion of breast cancer molecular




Archival materials from patients with breast cancer were initially
obtained from four institutions in West Africa between 1996 and 2004:
University of Calabar Teaching Hospital, Calabar, Nigeria; Usman Danfodio
University Teaching Hospital, Sokoto, Nigeria; Obafemi Awolowo University
Teaching Hospital, Ile-Ife, Nigeria; and Institut Pasteur, Dakar, Sénégal (from
three local pathology laboratories in Dakar). We identified all patients with
histologically confirmed breast cancer who were consecutively treated in these
institutions or whose samples were received in these pathology laboratories.
All samples were formalin-fixed and paraffin-embedded (FFPE) according to
routine surgical pathology practice. In total, 378 eligible cases were included in
the final analysis.
In 2005, we established a breast cancer laboratory within the Institute
for Medical Research and Training at the University of Ibadan, Nigeria, to
provide core research support and clinical services to all Nigerian medical
institutions. Through this laboratory, FFPE tissues of patients with breast
cancer were collected using standard tissue handling guidelines to main-
tain integrity of the tissue blocks. This report includes a replicate sample of
129 patients with histologically confirmed breast cancer who were received
in the laboratory by the end of 2007 and were treated mainly at the
University College Hospital at Ibadan (47%) and Ebonyi State University
Teaching Hospital at Abakaliki (42%). The study was approved by institu-
tional review boards of the coordinating institutions in Ibadan and Calabar
and the University of Chicago.
Pathologic Assessment and Construction of
Tissue Microarray
Pathologic features, including histologic diagnosis, grade, tumor size,
and axillary lymph node metastasis, were abstracted from pathologic reports
and evaluated separately by the two study pathologists (F. Ikpatt, A.K.). Whole
sections of archival slides stained with hematoxylin and eosin were evaluated
for volume-corrected mitotic index expressed as mitoses per square millime-
ter, mean nuclear area, and fraction of fields with tubular differentiation. The
histology grading of invasive breast cancer was performed using the modified
Scarff-Bloom-Richardson system.18
Tissue microarrays were constructed from FFPE tumor samples and
adjacent histologic normal epithelium, which serve as an internal positive
control. Cores were precisely arrayed into a new recipient paraffin block using
the automated tissue microarrayer ATA-27 (Beecher Instruments, Silver
Spring, MD) with the method described by Kononen et al.19
Immunohistochemistry
Paraffin specimens were cut into 4-m sections and mounted on posi-
tively charged slides. The slides were deparaffinized and rehydrated in xylene
followed by graded alcohols, then washed in Tris-buffered saline.
Table 1. Source, Clone, and Dilution of Antibodies Used
Antibody Clone Dilution Source Pretreatment
ER SP1 1:50 NeoMarkers, Fremont, CA Microwave 30 minutes, citrate buffer (pH 6.0)
PR SP2 1:50 NeoMarkers Microwave 30 minutes, citrate buffer (pH 6.0)
HER2/neu HercepTest Ready to use DAKO, Carpinteria, CA Microwave 15 minutes, Epitope retrieval solution
(HercepTest cat K5207)
EGFR 2-18C9 Ready to use DAKO Proteinase K (DAKO, PharmDX, Code K1494)
Cytokeratin 5/6 D5/16 B4 1:100 DAKO Microwave 30 minutes, citrate buffer (pH 6.0)
VEGF-A A-20, sc-152 1:500 Santa Cruz Biotechnology, Santa Cruz, CA Microwave 30 minutes, citrate buffer (pH 6.0)
VEGF-C Z-CVC7, 18-2255 1:25 Zymed Laboratories, South San Francisco, CA Microwave 30 minutes, citrate buffer (pH 6.0)
Ki-67 Ki-S5 1:50 DAKO Microwave 15 minutes, Target Retrieval Solution
(DAKO, cat S3308)
P53 DO1 1:100 Oncogene, Cambridge, MA Microwave 30 minutes, citrate buffer (pH 6.0)
P63 4A4  Y4A3 1:100 NeoMarkers Microwave 15 minutes, Target Retrieval Solution
(DAKO, cat S3308)
BCL2 124 1:100 DAKO Microwave 30 minutes, citrate buffer (pH 6.0)
BCLXL Polyclonal rabbit 1:500 BD Pharmingen, San Diego, CA Microwave 30 minutes, citrate buffer (pH 6.0)
Cyclin D1 DSC-6 1:300 DAKO Microwave 30 minutes, citrate buffer (pH 6.0)
Cyclin E 13A3 1:100 Novocastra, Newcastle upon Tyne, United Kingdom Microwave 30 minutes, citrate buffer (pH 6.0)
IGF-1R 24-31 1:50 NeoMarkers Microwave 30 minutes, citrate buffer (pH 6.0)
Vimentin V9 1:50 DAKO None
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor;
VEGF, vascular endothelial growth factor; cat, catalog number; BCL2, B-cell lymphoma protein 2; BCLXL, B-cell lymphoma extra large protein; IGF-1R, insulin-like
growth factor 1 receptor.
Huo et al
4516 © 2009 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Immunohistochemical assays were performed using a DAKO immu-
nostainer (DAKO, Carpinteria, CA) with antibodies and antigen unmask-
ing as detailed in Table 1. Slides were incubated in 0.03% hydrogen peroxide
for 5 minutes to block endogenous peroxidase activity, followed by incubation
for 20 minutes in a protein-blocking solution (Protein Block Serum-free
solution, DAKO) to reduce nonspecific background. Envision reagents
(DAKO) were used as a detection system. Slides were then treated for 5
minutes with 3-3-diaminobenzidine chromogen, counterstained with hema-
toxylin, and coverslipped. Appropriate negative controls for the immuno-
staining were prepared by omitting the primary antibody step. The results of
immunostainings were scored semiquantitatively by two pathologists using
Reiner’s four-point scale based on intensity and percentage of IHC reaction.20
Epidermal growth factor receptor (EGFR) and HER2 stainings were evaluated
according to manufacturer’s instructions (DAKO).
Consistent with previous publication,11 breast cancer subtypes were
defined as luminal A (ER positive and/or PR positive, HER2 negative), luminal
B (ER positive and/or PR positive, HER2 positive), basal-like (ER negative, PR
negative, HER2 negative, CK5/6 positive, and/or EGFR positive), HER2 posi-
tive/ER negative (HER2 positive, ER negative, PR negative), and unclassified
(negative for all five markers).
Statistical Analysis
One-way analysis of variance was conducted to compare the difference in
age at diagnosis between breast cancer subtypes. Kruskal-Wallis tests were used
to compare tumor size, histologic grade, and morphometric measures be-
tween subtypes. Fisher’s exact tests were used to examine the relationship
between categorical pathologic characteristics and subtypes. Hierarchical clus-
ter analysis with average linkage algorithms21 was performed to explore tumor
subtypes based on immunohistochemical data. Clustering analysis was done
with Cluster.21 Other statistical analyses were done with STATA 9.2 (STATA,
College Station, TX).
















PNo. % No. % No. % No. % No. % No. %
Age, years
 50 251 66 70 69 6 67 69 67 35 61 71 66 .92
 50 127 34 32 31 3 33 34 33 22 39 36 34
Mean 44.8 44.2 44.8 44.4 45.9 45.1 .91
SD 11.8 12.2 10.5 11.0 11.7 12.4
Site .14
Calabar, Nigeria 148 39 42 41 3 33 34 33 26 46 43 40
Ile-Ife, Nigeria 54 14 13 13 0 23 22 9 16 9 8
Sokoto, Nigeria 30 8 9 9 1 11 11 11 4 7 5 5
Senegal 146 39 38 37 5 56 35 34 18 32 50 47
Positive lymph nodes 271 72 64 63 4 44 82 80 41 72 80 75 .03
Tumor size, cm
 2.0 21 6 5 5 0 6 6 4 7 6 6 .96
2.1-4.0 209 55 57 56 4 44 55 53 27 47 66 62
 4.0 148 39 40 39 5 56 42 41 26 46 35 33
Histologic grade  .0001
Well differentiated 65 17 44 43 1 11 2 2 2 4 16 15
Moderately differentiated 145 38 48 47 4 44 32 31 7 12 54 51
Poorly differentiated 168 44 10 10 4 44 69 67 48 84 37 35
Histologic type .0003
Ductal 328 87 85 83 8 89 92 89 54 95 89 83
Medullary 13 3 0 0 6 6 1 2 6 6
Metaplastic 14 4 0 0 3 3 2 4 9 8
Lobular 14 4 13 13 0 0 0 1 1
Tubular 5 1 4 4 1 11 0 0 0
Colloid 4 1 0 0 2 2 0 2 2
Mitotic index  .0001
Median 27 18 30 31 44 25
IQR 19-34 10-22 26-44 27-37 39-46 18-30
MNA  .0001
Median 54 34 57 60 73 49
IQR 40-63 25-45 49-75 55-66 63-83 39-57
FTD  .0001
Median 10 25 10 7 5 10
IQR 5-20 15-50 0-15 5-10 0-5 7-20
MVD  .0001
Median 6.1 5.2 8.8 6.5 8.7 5.5
IQR 5.1-7.4 3.8-6.7 5.3-10.4 5.9-7.4 7.6-10.5 4.8-6.2
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; SD, standard deviation; IQR, interquartile range; MNA, mean nuclear area;
FTD, fraction of fields with tubular differentiation; MVD, microvessel density.
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RESULTS
A total of 507 patients with invasive breast cancer from Nigeria and
Senegal were included in the study. In the first cohort of 378 patients,
the mean age was 44.8 years, and only 12% were older than 60 years.
Almost all tumors were larger than 2.0 cm, and more than two thirds
of the cases were lymph node positive. More than 80% of the cases
were of intermediate and high grade, with the majority being of ductal
histology. IHC analysis revealed that 24%, 20%, and 17% of tumors
were positive for ER, PR, and HER2, respectively. The majority of
tumors were basal-like or unclassified subtypes (27% and 28%, re-
spectively). Only 29% were luminal A or B, and 15% were HER2-
positive/ER-negative subtype.
Table 2 shows the distribution of clinicopathologic characteris-
tics by the five molecular subtypes. Prevalence of these molecular
subtypes was independent of study site, age, and tumor size. Lack of
association with age may due to narrow range of age distribution in
this relatively young cohort. Subtype was highly significantly associ-
ated with histologic grade and the four tumor morphometric param-
eters (all P  .0001). HER2-positive/ER-negative subtype had the
highest grade, followed by basal-like. Luminal tumors had the lowest
grade, with unclassified tumors in between. The molecular subtypes
also differed by histologic type: metaplastic and medullary tumors
were in the basal-like, HER2-positive/ER-negative, or unclassified cat-
egories, whereas almost all lobular tumors were classified into luminal
A and B subtypes. The association between subtype and lymph node
metastasis was marginally significant in the crude analysis but not
significant after adjusting for histologic grade.
Because of concern for antigen degradation of archived speci-
mens, 10 additional IHC markers were examined. We found at least
one of the 10 markers was positive for all hormone receptor–negative
tumors, and at least five markers were positive for 83% of the hormone
receptor–negative tumors. Table 3 shows the distribution of all these
markers was significantly different between molecular subtypes. Spe-
cifically, luminal A subtype tumors were less likely to express prolifer-
ation markers, such as Ki67, than other subtypes. P53 mutation was
more likely to be present among basal-like, HER2-positive/ER-
negative, and luminal B subtypes. BCL2 overexpression was observed
among luminal A tumors, whereas BCLXL overexpression was ob-
served among basal-like and HER2-positive/ER-negative tumors.
Hierarchical clustering analysis of all 15 IHC markers demon-
strated that the established IHC-based subtype classification could
be validated among tumors from West Africa, but nearly one third
of the tumors were unclassified (Fig 1). The two large branches
probably represent tumors with good and bad prognosis. The
dendrogram also suggests that the unclassified tumors can be fur-
ther divided into two distinct clusters. Interestingly, one cluster
was under the “good” prognosis branch, characterized as BCL2
positive and Cyclin D1 positive, and the other cluster was under the
“bad” prognosis branch, with a molecular portrait of vascular
endothelial growth factor (VEGF) –A positive, VEGF-C positive,
BCLXL positive, and Cyclin E positive.
On the basis of the cluster analysis, we categorized the unclassi-
fied cases into two subgroups: 86 patients in the VEGF-positive sub-
group (VEGF-A positive or VEGF-C positive) and 21 patients in the
VEGF-negative subgroup (negative for both VEGF-A and VEGF-C).
The VEGF-positive subgroup had significantly worse histologic grade
(42% grade 3 and 56% grade 2) than the VEGF-negative subgroup
(5% grade 3 and 29% grade 2; P  .0001). The VEGF-positive sub-
group also had significantly higher mitotic index, mean nuclear area,
and microvessel density and lower fraction of fields with tubular
differentiation than the VEGF-negative subgroup (all P  .0001). The
two subgroups were similar in tumor size, lymph node status, and
histologic type. Interestingly, the VEGF-negative subgroup had better
grade, mitotic index, mean nuclear area, and microvessel density than

















PNo. % No. % No. % No. % No. % No. %
ER 92 24 85 83 7 78 0 0 0
PR 76 20 72 71 4 44 0 0 0
HER2 66 17 0 9 100 0 57 100 0
Cytokeratin 5/6 123 33 5 5 3 33 82 80 33 58 0
EGFR 136 36 4 4 2 22 96 93 34 60 0
VEGF-A 281 74 58 57 9 100 86 84 50 88 78 73  .0001
VEGF-C 255 67 46 45 6 67 76 74 48 84 79 74  .0001
Ki67 328 87 66 65 9 100 102 99 55 96 96 90  .0001
P53 133 35 15 15 7 78 53 51 38 67 20 19  .0001
P63 43 11 0 2 22 9 9 22 39 10 9  .0001
BCL2 130 34 83 81 2 22 8 8 1 2 36 34  .0001
BCLXL 243 64 22 22 3 33 98 95 54 95 66 62  .0001
Cyclin D1 171 45 87 85 1 11 19 19 7 12 57 53  .0001
Cyclin E 226 60 22 22 5 56 91 88 52 91 56 52  .0001
IGF-1R 257 68 73 72 8 89 73 71 45 79 58 54 .005
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor;
VEGF, vascular endothelial growth factor; BCL2, B-cell lymphoma protein 2; BCLXL, B-cell lymphoma extra-large protein; IGF-1R, insulin-like growth factor 1 receptor.
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the luminal A subtype (all P  .05), suggesting that these VEGF-
negative tumors are less likely to represent ER-positive cases that were
false negatives.
To replicate our initial findings, an additional 129 African
tumors were studied. The proportion of ER-positive, PR-positive,
and HER2-positive tumors was 27%, 17%, and 16%, respectively.
In this second cohort, the proportion of the five molecular sub-
types was 33% luminal A, 3% luminal B, 23% basal-like, 14%
HER2 positive/ER negative, and 27% unclassified, which were
quite similar to those in the first cohort.
DISCUSSION
In this study of more than 500 patients with breast cancer from
different geographic regions in West Africa, we found that hormone
receptor–negative breast cancer is predominant, and only 25% were
ER positive. This finding is consistent with two studies conducted in
Nigeria, which reported 25% and 24% ER positive in 178 and 124
cases, respectively,22,23 but different from another Nigerian study,
which reported 71% ER positive in 177 cases.24 The proportion of
ER-positive breast cancer in blacks living in the United States and
United Kingdom has been consistently reported between 61% and
66% in most studies and the Surveillance, Epidemiology, and End
Results (SEER) database.6,7 To have a fair comparison, we calculated
the age-standardized proportion of ER-positive tumors for African
Americans by applying the age-specific proportions of ER-positive
tumors from the SEER program25 to age distribution of the study
cohort in West Africans. We found the expected proportion of ER-
positive tumors for African Americans would be 55% if they had the
same age distribution as the African cohort. Thus although the African
cohort is young as a result of the relatively short life expectancy of the
population (49.1 years in Nigeria and 60.7 years in Senegal), the
observed 25% is much lower than expected based on SEER data.
We used hierarchical clustering analysis of IHC markers to
demonstrate that the predefined subtype classification is concor-
dant with the self-organized clusters. The distribution of breast
cancer subtypes seems to vary across populations based on our
results and published literature for unknown reasons.14,26,27 Lumi-
nal A breast cancers were predominant in Asian, white, and




















Interpretable or weak positive
Missing
Fig 1. Hierarchical clustering of 378 invasive breast tumors from West Africa using 15 immunohistochemical markers. LumA, luminal A; LumB, luminal B; HER2,
human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor; EGFR, epidermal growth factor receptor; BCL2, B-cell lymphoma protein
2; VEGF, vascular endothelial growth factor; BCLXL, B-cell lymphoma extra-large protein; IGF-1R, insulin-like growth factor 1 receptor.
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approximately 40% in premenopausal African Americans, and only
27% in indigenous Africans. In contrast, the proportion of basal-like
subtype was 27% in indigenous Africans and premenopausal African
Americans, approximately 15% in postmenopausal African Ameri-
cans and premenopausal European Americans, and only approxi-
mately 10% in other populations. There is also a clear gradient in the
proportion of unclassified breast tumors across populations, with
Africans having the highest proportion. Interestingly, the proportion
of HER2-positive tumors (luminal B and HER2-positive/ER-negative
subtypes combined) seems similar in all populations.
Our findings have implications for breast cancer prevention
and treatment. First, the striking difference in subtype distribution
across populations suggests heterogeneity in etiology. Tumor sub-
type is strongly associated with grade, but not or only weakly
associated with lymph node metastasis and tumor size, suggesting that
subtype is “intrinsic” and predetermined. The comparison of subtype
spectrum between whites, African Americans, and indigenous Afri-
cans suggests that both environmental exposures and genetic back-
ground determine breast cancer subtypes. Indeed, recent studies have
found that breast cancer risk factors vary by tumor subtypes.14,27
Second, our study findings suggest that triple-negative and basal-like
breast cancer are not synonymous. Basal markers, such as basal cyto-
keratins and EGFR, are useful to identify true basal-like breast
cancer.10,11,28 In fact, unclassified tumors (nonbasal, triple-negative
tumors) are histologically less aggressive than basal-like tumors but
more aggressive than luminal A tumors in our study and those of
others.11,14 Using hierarchical clustering analysis, we also showed that
unclassified tumors are not homogenous, and two subgroups (VEGF-
positive and VEGF-negative subgroup) emerged with distinct pat-
terns of tumor aggressiveness.
Caution should be exercised when interpreting our finding of
high frequency of hormone receptor negativity. Antigen degradation
of archival materials may cause false-negative results,24 but we took
several steps to address this issue. First, IHC analysis of the second
cohort confirmed findings from the initial cohort. Second, vimentin
served as an internal control to monitor quality of tissue fixation in
archival tumors. Specimens with negative vimentin stromal staining
(approximately 1%) were excluded in the final analysis. Consistent
with previous study,29 vimentin expression in tumors was associated
with the basal-like phenotype (data not shown). Third, tissue microar-
rays were constructed from FFPE tumor samples and adjacent histo-
logic normal epithelium (where available), which serve as an internal
positive control. Fourth, tumor blocks with inadequate or question-
able material were excluded. As an indirect validation of our assess-
ment of ER status, we found ER-negative breast cancer subtypes were
associated with higher grade, unfavorable histologic phenotype, and
higher proliferative capacity, which is consistent with previous stud-
ies.11,14,26 Taken together, it is unlikely that the low ER-positive pro-
portion we observed is purely due to poor antigen retrieval but rather
reflects the biology of these tumors.
Although we acknowledge that the prevalence of breast cancer
subtypes observed in this study may not reflect the diversity in the
entire African breast cancer patient population, unselected consecu-
tive samples from several institutions were assayed. This study was
conducted in two impoverished African countries where access to
health care is limited, so underdiagnosis and delayed diagnosis are
possible. On one hand, patients with rapidly progressive breast cancer
are more likely to die before going to the hospital, generating bias
toward a higher proportion of ER-positive tumors. However, patients
with aggressive disease may be more likely to be referred to tertiary
hospitals for cancer diagnosis and treatment, which generates bias
toward a lower proportion of ER-positive tumors. Given the relatively
poor health infrastructure in both countries, it is unlikely that there is
a referral bias, as most community providers lack the infrastructure to
treat patients with cancer. It is also unlikely that delayed diagnosis is an
important factor because breast cancer subtype was only weakly asso-
ciated with tumor stage. Because hospital-based cases referred to pa-
thology departments were the only source of reliable data for studying
cancer molecular subtype in these countries, it is reassuring that the
age distribution of our study cohort was similar to that in the Ibadan
Cancer Registry in Nigeria (mean age  standard deviation, 46.5 
12.1 years), which suggests selection or referral bias is minimal.
In summary, our study suggests that hormone receptor–negative
breast cancer is predominant, and triple-negative tumors, including
basal-like and unclassified subtypes, represent the majority of tumors
in West African patients with breast cancer. These findings partly
explain the poor prognosis of breast cancer in African women and
have important clinical and policy implications for breast cancer con-
trol in Africa. Mammographic screening may not work and low re-
source treatments such as oophorectomy or tamoxifen may be
ineffective without knowledge of the patient’s hormone receptor sta-
tus. It underscores the urgent need for research into the etiology and
pathogenesis of the aggressive molecular subtypes that disproportion-
ately affect young women of African ancestry. Only then can we begin
to close the gaps in the global disparities in breast cancer outcomes
across populations.
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